Brokerages Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $6.60

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have received a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.60.

Several equities analysts recently issued reports on the company. HC Wainwright reduced their price objective on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Morgan Stanley cut TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Finally, Needham & Company LLC cut their price objective on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th.

TScan Therapeutics Price Performance

TCRX opened at $1.04 on Friday. The stock has a market capitalization of $59.02 million, a PE ratio of -0.93 and a beta of 1.04. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The company’s 50 day simple moving average is $1.06 and its 200 day simple moving average is $1.53. TScan Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.67.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. The company had revenue of $2.51 million during the quarter, compared to analyst estimates of $1.98 million. As a group, sell-side analysts expect that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Activity

In related news, major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average cost of $0.90 per share, with a total value of $67,950.00. Following the completion of the transaction, the insider owned 8,012,916 shares of the company’s stock, valued at approximately $7,211,624.40. This trade represents a 0.95% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased 161,801 shares of company stock valued at $145,621 over the last ninety days. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of TScan Therapeutics

Several large investors have recently made changes to their positions in TCRX. Catalyst Funds Management Pty Ltd acquired a new position in shares of TScan Therapeutics during the second quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of TScan Therapeutics during the 2nd quarter worth about $29,000. Quadrature Capital Ltd acquired a new position in shares of TScan Therapeutics in the 2nd quarter worth approximately $33,000. Boothbay Fund Management LLC boosted its stake in TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in TScan Therapeutics during the 2nd quarter worth about $78,000. Institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.